ClinicalTrials.gg
CompletedNCT07346638BEAR-SIUpdated Oct 16, 2026

The BEAR Program for Women With Trauma Who Have Suicidal Thoughts

An interventional study of BEAR-SI in Interpersonal Trauma, Depression and PTSD, sponsored by Stanford University. Completed at 1 site in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Depression by Stanford University — 15 open to participants now, 17 under way, none of them phase 3. Depression · Stanford University.

Enrollment
56th of 64
5 · median 40
Started
2026
with 7 others
No phase
45 of 77
12 open now
Registered
73rd of 77
by date

Among the 77 studies in Depression by Stanford University, this one is the 56th largest by enrollment of the 64 interventional ones that give a count, is one of 8 that started in 2026, is one of 45 with no phase, and was the 73rd registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

15 of the 77 studies in Depression by Stanford University are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Depression by Stanford University, or all of them as a file.
02

Study summary

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Read the detailed description

In the US, approximately 36% of women experience some type of sexual violence in their lifetime. Sexual violence can have a significant and lifelong impact on a women's life, with particularly high rates of mental health issues (e.g., depression, anxiety, PTSD). Women who are sexually assaulted have a three-fold risk of lifetime suicidal ideation and more than a five-fold elevated risk of suicide attempts compared to women who have not been sexually assaulted. Women who are victimized are at higher risk of subsequent sexual victimizations, and with that, worsened well-being and an even higher suicide risk.

Empowerment self-defense (ESD) training has consistently been shown to reduce the risk of both attempted and completed sexual assault by approximately 50%. Survivors of rape who participate in such training demonstrate decreases in PTSD symptoms and self-blame for past assaults. Increases in perceived self-efficacy is one of the positive outcomes of ESD work. Perceived self-efficacy is one's beliefs about their competency and capabilities to perform and is a key factor of how people think, behave, feel, and motivate themselves and how they respond in various situations, including risky or traumatic situations. Higher coping self-efficacy buffers individuals who experience trauma from posttraumatic distress, and separately, higher self-efficacy has been shown to be a protective factor against suicidality in several populations.

The purpose of the current study is to test the feasibility of the Building Empowerment and Resilience (BEAR) program which was adapted for women who have a history of sexual violence and currently endorse suicidal thinking. The Building Empowerment and Resilience-SI (BEAR-SI) Therapeutic program incorporates psychological skills, psychoeducation, and physical self-defense training, all within a therapeutic process. Our experience indicates survivors of sexual violence seek a more active intervention as they often continue to feel quite vulnerable with therapy alone. The program specifically addresses the sequalae of sexual assault and teaches skills for maintaining personal safety and for coping with unwanted thoughts, including suicidal thinking. Our goal is to determine the feasibility of the adapted BEAR program and if it enhances self-efficacy and decreases suicidal thoughts. This is a 12-week, in-person therapy group. We will examine pre- and post-group outcomes, as well as 3- and 12-month follow up.

03

Conditions studied

  • Interpersonal Trauma
  • Depression
  • PTSD
  • Anxiety
  • Suicidal Ideations
  • Sexual Assault

Keywords

  • interpersonal trauma
  • sexual assault
  • suicidal ideation
  • self-defense
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women ages 18-75
  • History of physical, sexual, and/or sexual emotional violence, with subsequent interpersonal or psychological distress (e.g., depression or anxiety) related to this history.
  • Current suicidal thinking

Exclusion criteria

Exclusion Criteria:

  • Active, significant substance abuse, which could interfere with participation
  • Significant medical conditions that would preclude safe participation in the study
  • No history of interpersonal trauma
  • Acute psychiatric instability
  • History of assaultive behavior or is judged to be a potential risk to assault others.
  • No current suicidal ideation or behaviors
  • Unable to commit to the group for 12 weeks in-person
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    BEAR therapy group

    BEAR therapy intervention

    Behavioral: BEAR-SI

Interventions

  • BehavioralBEAR-SI

    The BEAR Therapeutic program is a twelve-week group that meets once per week for 1.5 hours per week. The program includes three main components. The first is a psycho-educational component which provides current information about assault statistics, common risk factors, myths that are often associated assault, and safety related information The second component focuses on the development of an assortment of interpersonal skills. This part of the group offers skills such as assertiveness or communication training, boundary setting, and coping skills. The third component of our intervention consists of a thorough set of self-defense skills that help women to keep themselves safe. The repertoire of skills include recognizing unsafe situations, utilizing one's voice, and release from holds. This section provides ample practice blocks, resistance skills, and specific techniques to keep one's self safe.

06

What researchers measure

Primary outcomes

  1. Coping self-efficacy

    This scale ranges from 0-286, with 0 indicating no confidence in managing stressors to 286 indicating very high level of confidence that one could do a particular behavior

    Time frame: Baseline to 12 weeks (post-group)

  2. Beck Scale for Suicidal Ideation

    Assesses amount of suicidal thinking. The total BSS score can range from 0, with no suicidal thinking to 38 points, severe level of suicidal thinking.

    Time frame: Baseline to 12 weeks (post-group)

Other outcomes

  1. Retention in the group

    Will examine number of participants who completed at least 10/12 sessions

    Time frame: 12 weeks (post-group)

07

Study locations

1 site
  • Stanford University School of Medicine
    Stanford, California 94305, United States
08

References and documents

Publications

  • Hollander, J. A., & Cunningham, J. (2020). Empowerment Self-Defense Training in a Community Population. Psychology of Women Quarterly, 44(2), 187-202. https://doi-org.laneproxy.stanford.edu/10.1177/0361684319897937
  • Smith, S.G., et al. (2017). The National Intimate Partner and Sexual Violence Survey (NISVS): 2010-2012 State Report. Atlanta, GA: National Center for Injury Prevention and Control, Centers for Disease Control and Prevention.
  • Denneson LM, Smolenski DJ, Bauer BW, Dobscha SK, Bush NE. The Mediating Role of Coping Self-Efficacy in Hope Box Use and Suicidal Ideation Severity. Arch Suicide Res. 2019 Apr-Jun;23(2):234-246. doi: 10.1080/13811118.2018.1456383. Epub 2018 Jul 11. PubMed 29624123 ↗
  • Cieslak R, Benight CC, Caden Lehman V. Coping self-efficacy mediates the effects of negative cognitions on posttraumatic distress. Behav Res Ther. 2008 Jul;46(7):788-98. doi: 10.1016/j.brat.2008.03.007. Epub 2008 Mar 18. PubMed 18456241 ↗
  • Dworkin ER, DeCou CR, Fitzpatrick S. Associations between sexual assault and suicidal thoughts and behavior: A meta-analysis. Psychol Trauma. 2022 Oct;14(7):1208-1211. doi: 10.1037/tra0000570. Epub 2020 Mar 23. PubMed 32202845 ↗

Individual participant data

Plan to share: No — This is a pilot study to determine the feasibility of this group. We will be collecting both qualitative and quantitative data on a small group of participants.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Sep 2026, 6 months.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Aug 2027 → Sep 2026 and completion Aug 2028 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 16, 2026
StartActual
Feb 17, 2026
Primary completionActual
Sep 1, 2026was Aug 2027
CompletionActual
Sep 1, 2026was Aug 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Primary completion
Aug 2027→Sep 1, 2026 (actual)
Oct 16, 2026
Study completion
Aug 2028→Sep 1, 2026 (actual)
Oct 16, 2026
Enrollment
30 (estimated)→5 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    Primary completion Aug 2027→Sep 1, 2026 (now actual)
    Study completion Aug 2028→Sep 1, 2026 (now actual)
    Enrollment 30 (estimated)→5 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07346638
Responsible party
Jennifer Keller (Clinical Professor, Stanford University) — Principal investigator
First posted
Jan 16, 2026
Start date
Feb 17, 2026
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Oct 16, 2026

Study contacts

Jennifer Keller, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion